Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics
Rosetta is an emerging molecular diagnostics company focused on molecular testing of cancer and other diseases using the company's unique and proprietary microRNA platform technology.
Rosetta Genomics Announces Publication of Data Correlating miR-150 to ...
The abstract and full article can be accessed at http://www.ncbi.nlm.nih.gov/pubmed/24462065 .
Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic
The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of technology in the development of cancer therapeutics associated with non-small cell lung cancer in p53-negative patients.
MacReport Media RSS Feed
Rosetta Genomics Executes Agreement With MultiPlan
Together with Medicare reimbursement, we estimate that the total number of covered lives for which our Cancer Origin Test could be adjudicated as 'in-network' exceeds 170 million," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.